Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
In Guru Portfolios
Manager | Fund | Portfolio Weight (%) | Change |
|---|---|---|---|
| Kenneth Griffin | CITADEL ADVISORS LLC | 0.0% | -0.00% |
| Steven Cohen | Point72 Asset Management, L.P. | 0.0% | +0.00% |
About
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of APGE is 135 and suggests 0.256% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendatio